These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 8093030)
1. Combination of the chemotherapeutic agent 5-fluorouracil with an inhibitor of its catabolism results in increased micronucleus induction. Stopper H; Kühnel A; Podschun B Biochem Biophys Res Commun; 1994 Sep; 203(2):1124-30. PubMed ID: 8093030 [TBL] [Abstract][Full Text] [Related]
2. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase. Tuchman M; Ramnaraine ML; O'Dea RF Cancer Res; 1985 Nov; 45(11 Pt 1):5553-6. PubMed ID: 4053028 [TBL] [Abstract][Full Text] [Related]
3. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Desgranges C; Razaka G; De Clercq E; Herdewijn P; Balzarini J; Drouillet F; Bricaud H Cancer Res; 1986 Mar; 46(3):1094-101. PubMed ID: 3943086 [TBL] [Abstract][Full Text] [Related]
4. Porcine recombinant dihydropyrimidine dehydrogenase: comparison of the spectroscopic and catalytic properties of the wild-type and C671A mutant enzymes. Rosenbaum K; Jahnke K; Curti B; Hagen WR; Schnackerz KD; Vanoni MA Biochemistry; 1998 Dec; 37(50):17598-609. PubMed ID: 9860876 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Tatsumi K; Fukushima M; Shirasaka T; Fujii S Jpn J Cancer Res; 1987 Jul; 78(7):748-55. PubMed ID: 3114201 [TBL] [Abstract][Full Text] [Related]
6. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil. Naguib FN; Hao SN; el Kouni MH Cancer Res; 1994 Oct; 54(19):5166-70. PubMed ID: 7923135 [TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071 [TBL] [Abstract][Full Text] [Related]
8. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy. Adams ER; Leffert JJ; Craig DJ; Spector T; Pizzorno G Cancer Res; 1999 Jan; 59(1):122-7. PubMed ID: 9892196 [TBL] [Abstract][Full Text] [Related]
9. [Determination of dihydropyrimidine dehydrogenase in the prediction of toxic side effects of 5-fluorouracil]. Katona C; Rosta A; Tóth K; Fónyad G; Jeney A; Pandi E; Kralovánszky J Orv Hetil; 1997 Jul; 138(29):1843-7. PubMed ID: 9280881 [TBL] [Abstract][Full Text] [Related]
10. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor. Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530 [TBL] [Abstract][Full Text] [Related]
11. [Intratumoral dihydropyrimidine dehydrogenase and its inhibition: a new approach in the pharmacokinetics of 5-fluorouracil]. Milano G; Etienne MC; Fischel JL Ann Gastroenterol Hepatol (Paris); 1995; 31(2):103-5. PubMed ID: 7618831 [No Abstract] [Full Text] [Related]
12. Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Inoue K; Takao M; Watanabe F; Tarukawa T; Shimamoto A; Kaneda M; Sakai T; Fukushima M; Shimpo H; Yada I Lung Cancer; 2005 Jul; 49(1):47-54. PubMed ID: 15949589 [TBL] [Abstract][Full Text] [Related]
13. [5-fluorouracil and dihydropyrimidine dehydrogenase]. Kubota T Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine. Peck R; Wiggs R; Callaghan J; Wootton R; Crome P; Fraser I; Frick L; Posner J Clin Pharmacol Ther; 1996 Jan; 59(1):22-31. PubMed ID: 8549030 [TBL] [Abstract][Full Text] [Related]
15. The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer. Li Y; Mizutani Y; Shiraishi T; Nakamura T; Mikami K; Takaha N; Okihara K; Kawauchi A; Sakai T; Miki T BJU Int; 2007 Mar; 99(3):663-8. PubMed ID: 17092280 [TBL] [Abstract][Full Text] [Related]
16. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. Komatsu T; Yamazaki H; Shimada N; Nagayama S; Kawaguchi Y; Nakajima M; Yokoi T Clin Cancer Res; 2001 Mar; 7(3):675-81. PubMed ID: 11297264 [TBL] [Abstract][Full Text] [Related]
17. Enzymes of uracil catabolism in normal and neoplastic human tissues. Naguib FN; el Kouni MH; Cha S Cancer Res; 1985 Nov; 45(11 Pt 1):5405-12. PubMed ID: 3931905 [TBL] [Abstract][Full Text] [Related]
18. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Jiang W; Lu Z; He Y; Diasio RB Clin Cancer Res; 1997 Mar; 3(3):395-9. PubMed ID: 9815697 [TBL] [Abstract][Full Text] [Related]
19. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma. Kim R; Tanabe K; Inoue H; Toge T Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567 [TBL] [Abstract][Full Text] [Related]
20. Induction of micronucleated erythrocytes in mouse peripheral blood after cutaneous application of 5-fluorouracil. Zúñiga-González GM; Torres-Bugarín O; Zamora-Perez AL; Gómez-Meda BC; Ramos-Ibarra ML; Gallegos-Arreola P; Flores-García A; López-Uribe A Arch Med Res; 2003; 34(2):141-4. PubMed ID: 12700011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]